Key result
Captopril completely inhibited bFGF-induced corneal neovascularization in rats and significantly slowed the growth of experimental fibrosarcomas, demonstrating direct antiangiogenic activity.
Why the study?
Does captopril inhibit angiogenesis and tumor growth in experimental rat models?
Population
Rats and capillary endothelial cells in vitro
Design
Preclinical
Authors
Loading...
Captopril's antiangiogenic activity at clinical doses warrants caution where neovascularization is desired; leaves open repurposing potential in angiogenesis-related disease.
Does captopril inhibit angiogenesis and tumor growth in experimental rat models?
Absolute Event Rate: 0% vs 100%
Captopril demonstrates antiangiogenic and antitumor activity in experimental rat models, suggesting potential unexpected benefits for patients on long-term therapy.
Volpert et al. (1996) studied Experimental angiogenesis and tumor growth. Captopril vs. Control (no captopril) was evaluated on Corneal neovascularization induced by bFGF. Captopril completely inhibited bFGF-induced corneal neovascularization in rats and significantly slowed the growth of experimental fibrosarcomas, demonstrating direct antiangiogenic activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: